T-cell therapy using interleukin-21-primed cytotoxic T-cell lymphocytes combined with cytotoxic T-cell lymphocyte antigen-4 blockade results in long-term cell persistence and durable tumor regression Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms
  • Melanoma
  • Programmed Cell Death 1 Receptor
  • Skin Neoplasms

abstract

  • We demonstrate that combining antigen-specific CTLs with CTLA-4 blockade is safe and produces durable clinical responses, likely reflecting both enhanced activity of transferred cells and improved recruitment of new responses, highlighting the promise of this strategy.

publication date

  • November 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5477923

Digital Object Identifier (DOI)

  • 10.1200/JCO.2015.65.5142

PubMed ID

  • 27269940

Additional Document Info

start page

  • 3787

end page

  • 3795

volume

  • 34

number

  • 31